Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05529069 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
A Phase 2 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05529069: Recruiting Phase 2 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, sponsored by M.D. Anderson Cancer Center.
NCT05529069 is a Phase 2 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05529069, a Phase 2 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Pirtobrutinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2027-04-28 |
| Phase | Phase 2 |
What NCT05529069 shows while recruiting
NCT05529069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT05529069 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05529069 about?
NCT05529069 is a clinical study titled "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients". To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).
What is the current status of trial NCT05529069?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-01-25. Estimated completion is 2027-04-28.
What conditions does trial NCT05529069 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Hematologic Malignancy.
What interventions are being tested in trial NCT05529069?
The interventions under investigation include: Venetoclax (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT05529069?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05529069 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05529069's enrollment target sits among peer trials
30 74th of 106 higher than 30 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI